COVID-19 Rapid Antigen Test

The proprietary sourced Nanotech COVID-19 Lateral Flow Assay is an immunochromatographic assay for the qualitative detection of the spike protein antigen from SARS-CoV-2 in nasopharyngeal (NP) swab specimens from individuals who are suspected of COVID-19.

Clinical Performance:
Sensitivity: 84.6% (94% within first 8 days of onset of symptoms)
Specificity: 90.0% (94% within 8 days of onset of symptoms)
Clinical Study Population: Clinical performance characteristics of the proprietary sourced COVID-19 antigen test was evaluated in a prospective study, at two different sites, where 99 patients were enrolled into the study and tested. Patients were a mix of symptomatic patients suspected of COVID-19 (59) and asymptomatic (40) patients.

Contents:

  • Nanotech COVID-19 LFA x 25
  • COVID-19 LFA Test Cartridge x 25
  • 1.5ml Microfuge Tube x 25
  • Dual Bulb Fixed Volume Pastette® (100μL) x 25
  • COVID-19 Reagent Solution Dropper Bottle (White Cap) 2 x 15ml
  • Instructions for use x 1
  • Procedure Card x 1
  • 25 Nasopharyngeal Swabs

Ideal for use at Airports, Private clinics, Industry, Schools

Download brochure: COVID 19 Lateral Flow Assay

Description

Intended Use: COVID-19 Lateral Flow Assay is an immunochromatographic assay for the qualitative detection of the spike protein antigen from SARS-CoV-2 in nasopharyngeal (NP)swab specimens from individuals who are suspected of COVID-19 by their healthcare provider. The assay is intended for professional and laboratory use.
Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. A positive result does not rule out co-infections with other pathogens. The agent detected may not be the definite cause of disease. The proprietary sourced Nanotech COVID-19 Lateral Flow Assay does not differentiate between SARS-CoV and SARS-CoV-2.
Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results do not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. The proprietary sourced Nanotech COVID-19 Lateral Flow Assay is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings.